Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBT Margin (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed EBT Margin for 14 consecutive years, with 29.72% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 382.0% year-over-year to 29.72%, compared with a TTM value of 24.66% through Dec 2025, up 403.0%, and an annual FY2025 reading of 24.66%, up 403.0% over the prior year.
  • EBT Margin was 29.72% for Q4 2025 at Neurocrine Biosciences, down from 36.71% in the prior quarter.
  • Across five years, EBT Margin topped out at 383.33% in Q2 2021 and bottomed at 24.57% in Q1 2023.
  • Average EBT Margin over 4 years is 42.74%, with a median of 23.2% recorded in 2025.
  • The sharpest move saw EBT Margin skyrocketed 35582bps in 2021, then crashed -1257bps in 2024.
  • Year by year, EBT Margin stood at 10.3% in 2021, then skyrocketed by 273bps to 38.47% in 2023, then crashed by -33bps to 25.9% in 2024, then rose by 15bps to 29.72% in 2025.
  • Business Quant data shows EBT Margin for NBIX at 29.72% in Q4 2025, 36.71% in Q3 2025, and 23.2% in Q2 2025.